Granules India, which has been on the block for a while may have found a buyer in large private equity firm Carlyle Group, which has been active on pharma investments, three independent sources with direct knowledge of the acquisition told CNBC.
They suggested that Carlyle is in advanced stages to acquire Granules India for around $1 billion. Carlyle is expected to buy promoter shares which will trigger an open offer to acquire additional stake from others. Carlyle recently acquired Sequent Scientific and bought a minority stake in Piramal Pharma.
Granules India has been exploring options to sell stake due to favourable valuations and succession issues. The company is into active pharmaceutical ingredients (APIs) and contract research and manufacturing (CRAMS).
Granules India did not comment on CNBC’s query on the deal development. PE firm Carlyle declined to comment.
Source: CNBC
Can’t stop reading? Read more
Triton prepares sale of damage restoration services firm Polygon
Buyout group Triton is preparing the sale of its damage restoration services firm Polygon in a...
Mytheresa IPO Pops As Trading Begins For Luxury E-Commerce Retailer
The fast-growing e-commerce business was the subject of a costly fight between Neiman, its private...
Shiseido in talks to sell lower-priced brands, deal reported at over $1.45 billion
Japanese cosmetics firm Shiseido Co Ltd said on Friday it was in talks to sell its lower-priced...